sciensano.be
Gepubliceerd op sciensano.be (https://www.sciensano.be)

Home > Biblio > Clinical Evolution and Disease Burden in Belgian Cystic Fibrosis Patients: effect of Newborn Screening?

Clinical Evolution and Disease Burden in Belgian Cystic Fibrosis Patients: effect of Newborn Screening?

[1]
Downloaden 147.08 KB [1]

Public Access

Published

Peer reviewed scientific article

Engels

DOI : https://belgjpaediatrics.com/index.php/bjp/article/view/104 [2]

Auteurs

Noelia Rodriguez Mier [3]; Vermeulen, François [4]; Géraldine Daneau [5]; Simeon Wanyama [6]; Proesmans, Marijke [7]

Trefwoorden

    Article written during project(s) : 
    BCFR Belgisch Mucoviscidose Register [8]

    Samenvatting:

    Objectives: We compared the clinical evolution and disease burden of 3 groups of Belgian children with cystic fibrosis (CF) depending on the mode of diagnosis: meconium ileus (MI), newborn screening (NBS) and clinical diagnosis (non-NBS) at 1-, 2- and 6 years of age.Methods: We conducted a retrospective observational cohort study based on data collected from the Belgian CF Registry report of 2016 including patients diagnosed between January 2006 and December 2016. Results: 306 CF patients were enrolled. Age at diagnosis was the lowest in MI patients (median 0.12 months, IQ…
    Lees meer

    Samenvatting

    Objectives: We compared the clinical evolution and disease burden of 3 groups of Belgian children with cystic fibrosis (CF) depending on the mode of diagnosis: meconium ileus (MI), newborn screening (NBS) and clinical diagnosis (non-NBS) at 1-, 2- and 6 years of age.Methods: We conducted a retrospective observational cohort study based on data collected from the Belgian CF Registry report of 2016 including patients diagnosed between January 2006 and December 2016.

    Results: 306 CF patients were enrolled. Age at diagnosis was the lowest in MI patients (median 0.12 months, IQR 0.00-0.36 months) but lower in NBS patients (median 1.38 months, IQR 0.82-1.74 months) compared to non-NBS patients (8.01 months, IQR 2.47-37.58 months, p-value < 0.001). Height z-scores at 1 year of age were better in NBS patients (median = -0.13, IQR -0.99 – 0.50) compared to non-NBS patients (MI median = -0.56, IQR = -01.53 – 0.02, non-NBS median = -0.54, IQR = -1.02 – 0.12, p = 0.03377). Annual prevalence of bacterial infections was not different between the 3 patient groups at the predefined time points. Burden of therapy was lower for NBS during the first 2 years of life. Lung function at 6 years of age did not show significant differences between the 3 groups.

    Conclusion: This study suggests a beneficial trend for NBS as primary method of CF detection when comparing age at diagnosis, clinical evolution and burden of therapy between NBS and clinically diagnosed CF patients. A standardized care program after CF-NBS is needed.

    Associated health topics:


    Source URL:https://www.sciensano.be/nl/biblio/clinical-evolution-and-disease-burden-belgian-cystic-fibrosis-patients-effect-newborn-screening-0

    Links
    [1] https://www.sciensano.be/sites/default/files/cf_newborn_screening.pdf [2] https://belgjpaediatrics.com/index.php/bjp/article/view/104 [3] https://www.sciensano.be/nl/biblio?f%5Bauthor%5D=89760&amp;f%5Bsearch%5D=Noelia%20Rodriguez%20Mier [4] https://www.sciensano.be/nl/biblio?f%5Bauthor%5D=50835&amp;f%5Bsearch%5D=Vermeulen%2C%20Fran%C3%A7ois [5] https://www.sciensano.be/nl/people/geraldine-daneau/biblio [6] https://www.sciensano.be/nl/people/simeon-situma-wanyama/biblio [7] https://www.sciensano.be/nl/biblio?f%5Bauthor%5D=50841&amp;f%5Bsearch%5D=Proesmans%2C%20Marijke [8] https://www.sciensano.be/nl/projecten/belgisch-mucoviscidose-register